Renowned USC/Norris Cancer Researcher, Dr. Heinz-Josef Lenz, Joins Panther Biotechnology Board of Directors
Marketwire - Thu Sep 11, 9:01AM CDT
Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced today that Heinz-Josef Lenz, M.D., F.A.C.P., associate director of clinical research at USC/Norris Comprehensive Cancer Center and co-chair of the Southwest Oncology Group's Gastrointestinal Committee, has been appointed to Panther Biotechnology's Board of Directors.
Panther Biotechnology, Inc. Announces a 6-1 Forward Stock Split to Increase Liquidity of Their Common Stock and Intent to List on the NYSE or NASDAQ
Marketwire - Mon Sep 08, 10:59AM CDT
Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced that a 6-1 forward stock split has been filed and has been approved by the Board of Directors of the Company and is subject to FINRA approval. The exact date of the split is still pending; however, the forward splitting of the common stock PBYA is being done to increase liquidity for current and future shareholders.
Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic
Marketwire - Tue Aug 26, 9:15AM CDT
Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.
Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic
eTeligis - Tue Aug 26, 9:01AM CDT
CHICAGO, IL, United States, via ETELIGIS INC., 08/26/2014 - - Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.